KalVista Pharmaceuticals recently announces Phase 3 KONFIDENT trial of Sebetralstat meets all primary and key secondary endpoints as first oral on-demand therapy for Hereditary Angioedema (HAE). HAE is a rare and potentially life-threatening genetic disease caused by low levels or dysfunction of the C1 inhibitor, associated with uncontrolled plasma kallikrein (PKa) activity and generation of bradykinin (BK).
Sebetralstat is an investigational novel, oral plasma kallikrein inhibitor with a favorable safety profile. It works by targeting the kallikrein–kinin system (KKS), reducing the activity of plasma kallikrein and blocking uncontrolled bradykinin release in HAE attack. The Phase 3 results also show rapid symptom relief in a broad HAE population.